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Abstract 
Non-classical human leucocyte antigen
(HLA)-G class I molecules have an important
role in tumor immune escape mechanisms. We
investigated HLA-G expression in lymphonode
biopsies taken from 8 controls and 20 patients
with advanced-stage classical Hodgkin lym-
phoma (cHL), in relationship to clinical out-
comes and the HLA-G 14-basepair (14-bp)
deletion-insertion (del-ins) polymorphism.
Lymphnode tissue sections were stained using
a specific murine monoclonal HLA-G antibody.
HLA-G protein expression was higher in cHL
patients than controls. In the group of PET-2
positive (positron emission tomography car-
ried out after 2 cycles of standard chemothera-
py) patients with a 2-year progression-free
survival rate (PFS) of 40%, we observed high
HLA-G protein expression within the
tumor microenvironment with low expression
on Hodgkin and Reed-Sternberg (HRS) cells.
Conversely, PET-2 negative patients with a PFS
of 86% had higher HLA-G protein expression
levels on HRS cells compared to the microenvi-
ronment. Lower expression on HRS cells was
significantly associated with the HLA-G 14-bp
ins/ins genotype. 
These preliminary data suggest that the
immunohistochemical pattern of HLA-G pro-
tein expression may represent a useful tool for
a tailored therapy in patients with cHL, based
on the modulation of HLA-G expression in rela-
tion to achievement of negative PET-2.
Introduction
Although cure rates in classical Hodgkin
lymphoma (cHL) range from 70 to 90%, a sig-
nificant proportion of patients fail to respond
to standard courses of chemotherapy and need
to be treated with intensified regimens that
carry an increased risk of long-term toxicities
and secondary cancer.1 It is of utmost impor-
tance to identify immune-biomarkers able to
predict poor responders patients to conven-
tional therapy that require intensification reg-
imens. cHL offers an interesting study model
for the identification of immunologic and
immunogenetic factors that may confer sus-
ceptibility to tumor or influence response to
treatment.2 The peculiar architecture of malig-
nant lymphogranuloma is characterized by the
presence of few neoplastic Hodgkin and Reed-
Sternberg (HRS) cells growing within a
microenvironment rich in immune system
cells incapable of mounting an effective antitu-
mor response.3,4
The aim of our study was to explore the role
of non-classical human leucocyte antigen
(HLA)-G class I molecules in tumor immune
escape mechanisms. These molecules are
encoded by a gene located on chromosome
6p21.3 of the major histocompatibility complex
(MHC).5 Alternative splicing can generate 7
different isoforms: 4 membrane isoforms (G1-
G4) and 3 soluble (s) isoforms (G5-G7). HLA-G
molecules are tolerogenic molecules expressed
in a restricted number of healthy tissues. They
exert their activity through interaction with
the human inhibitory receptors immunoglobu-
lin (Ig)-like transcript 2 (ILT2) and ILT4
expressed on natural killer (NK) cells, T and B
lymphocytes, dendritic cells and neutrophils.5
The role of HLA-G molecules in tumor-
escape have been described in several tumor
tissues and has been associated to cancer pro-
gression and an unfavorable outcome or prog-
nosis.6-8 In hematologic malignancies,
enhanced sHLA-G plasma levels, have been
found in B-cell malignancies, such as multiple
myeloma (MM), non-Hodgkin’s B-lymphoma
(NHL-B) and B-cell chronic lymphatic
leukemia (B-CLL).9,10 Different to what has
been observed in solid tumors,  the derived B
and T cells hematologic malignancies express
receptors recognized by HLA-G molecules.
Hence, the role played by HLA-G in oncohema-
tologic diseases is apparently more complex.
Some authors have shown that HLA-G inhibits
the proliferation of human B-cell lymphoma,
myelomas and B-cell leukemia through bind-
ing with ILT2 receptors.11 A correlation
between HLA-G expression, tumor onset and
clinical outcome has also been investigated in
MM, NHL-B and B-CLL.9,10,12,13 HRS cells are
ascribed to the B cell lineage and it is possible
that these cells express inhibitory receptors
capable of interacting with HLA-G molecules as
well as cells from the surrounding microenvi-
ronment. To the best of our knowledge, only
one study has addressed HLA-G expression in
cHL, but with no data on clinical outcomes.14 In
this study we investigated the expression of
HLA-G in lymphonode biopsies from patients
diagnosed with advanced-stage cHL, using a
specific murine monoclonal antibody.
Moreover, we evaluated the impact of HLA-G
expression on the tumor microenvironment
and HRS cells in patients who achieved nega-
tive results for [18F]-fluoro-2-deoxy-d-glucose
positron emission tomography carried out
after 2 cycles of standard chemotherapy (PET-
2). PET-2 is currently the most powerful pre-
dictor of treatment outcome in advanced-stage
cHL patients.15 Finally, we evaluated HLA-G
expression in relation to HLA-G allelic variants
characterized by a 14-basepair (14-bp) dele-
tion-insertion polymorphism located in exon 8
of the 3’-untranslated (UT) region of HLA-G,
that has been reported associated to different
levels of sHLA-G both in normal and pathologi-
cal conditions.16-18
                                    European Journal of Histochemistry 2016; volume 60:2606
Correspondence: Dr. Daniela Fanni, Istituto di
Anatomia Patologica, Dipartimento di Scienze
Chirurgiche, PO S. Giovanni di Dio, Università di
Cagliari, via Ospedale 60, 09124 Cagliari, Italy.
Tel. +39.070.6092372 – Fax: +39.070.6092370.
E-mail: fandan73@yahoo.it 
Contributions: GC, MG, GLN, conception and
design; GC, MG, DF, GS, RL, SL, CC, GF, GLN, data
collection and assembly; GC, PR, statistical analy-
sis; GC, MG, DF, GLN, manuscript writing. All
authors read and approved the final version of the
manuscript. 
Conflict of interest: the authors have no conflicts
of interest to disclose.
Acknowledgments: we are deeply grateful to all
the patients who participated in this study. We
are also grateful to Anna Maria Koopmans for
professional writing assistance. 
Received for publication: 20 December 2015.
Accepted for publication: 12 February 2016.
This work is licensed under a Creative Commons
Attribution-NonCommercial 4.0 International
License (CC BY-NC 4.0).
©Copyright G. Caocci et al., 2016
Licensee PAGEPress, Italy
European Journal of Histochemistry 2016; 60:2606
doi:10.4081/ejh.2016.2606
[European Journal of Histochemistry 2016; 60:2606] [page 1]










[page 2]                                               [European Journal of Histochemistry 2016; 60:2606]
Materials and MethodsPatients, controls and treatmentprotocols
Twenty patients with advanced-stage cHL
were recruited for the study. All patients were
enrolled in the HD607 multicenter clinical trial
investigating early treatment intensification
in patients with high-risk cHL, identified by
positive PET-2 scan after two conventional
chemotherapy courses. The study was per-
formed in accordance with the 1975 guidelines
of the Declaration of Helsinki and written
informed consent was obtained from all partic-
ipating patients. A complete data set contain-
ing all the following parameters was collected
at baseline and are reported in Table 1. The
patients received 2 courses of standard ABVD
(Doxorubicin, Bleomycin, Vinblastine,
Dacarbazine) treatment before undergoing
PET-2 to assess tumor chemosensitivity.
Patients were stratified into 2 groups accord-
ing to the results of PET-2. Patients with posi-
tive PET-2 were assigned to receive 4 courses
of escalated chemotherapy, followed by auto or
allotransplantation of hematopoietic stem cells
(HSC). Patients with negative PET-2 scan con-
tinued with 4 more courses of standard treat-
ment.  Controls
Tissue sections from lymphonodes diag-
nosed as normal or reactive obtained from 8
deceased subjects undergoing standard
immunologic characterization procedures for
organ donation were also used for control.HLA-G 14-basepair polymorphism
The presence of the 14-bp deletion/insertion
polymorphism in exon 8 of the 3’UT  region of
HLA-G was determined as previously
described.16 The patients were divided into
three groups according to HLA-G 14-bp geno-
type: homozygotes for the 14-bp insertion
(in/in), heterozygotes for the 14-bp
deletion/insertion (del/in) and homozygotes
for the 14-bp deletion (del/del). The 14-bp poly-
morphism of the HLA-G gene was analyzed
using polymerase chain reaction (PCR). Staining procedures
Tissue samples were fixed in 10% buffered
formalin, routinely processed and embedded in
paraffin. Serial sections 3 µm thick were
obtained from each paraffin block. Tissue sec-
tions were then dewaxed, rehydrated and pre-
treated for immunohistochemical analysis
with a 10-min heat-induced epitope retrieval
in buffer pH 9.00 (EnVisionTM FLEX Target
Retrieval Solution High pH - Dako Denmark
A/S, Glostrup, Denmark, Code K8004). Slides
were then incubated for 20 minutes at room
temperature with anti-human MHC Class I
HLA-G (LifeSpan BioSciences, Inc., Seattle,
WA, USA, Code LS-B3734) mouse monoclonal
antibody clone 4H84 at 1:100 dilution. Staining
procedures were performed with the
EnvisionTM FLEX+ (Dako, Code K8002)
Detection System and the AutostainerLink 48
instrument according to the manufacturer’s
instructions. The immunohistochemical evalu-
ation of HLA-G protein expression in stained
lymph node biopsy specimens was performed
by 3 independent pathologists according to the
following scores: 0 points for negative staining
(-), 1 for staining <25% of examined cells (-
+), 2 between 26 and 50% (+), 3 between 51
and 75% (++), 4 between 76 and 100% (+++).
The average agreement for the 3 assessed
variables among the three pathologists (DF,
GS, GF) was 80%, ranging from 70% for histio-
cytes, through 80% for lymphocytes, to 90% for
HRS cells.
Statistical analysis 
The probability of achieving progression
free survival (PFS) was calculated using the
Kaplan-Meier method. The log-rank test was
used to compare 2 groups of patients (negative
or positive PET). The magnitude of HLA-G
staining in lymphocytes, histiocytes and HRS
cells was compared between patients and con-
trols. Pearson’s chi-squared test and a two-
sided likelihood ratio test were applied. With
P-values below 5%, the results were confirmed
using the Fisher two-sided exact test at the
same level. Variables with a P-value lower than
0.2 in univariate analysis were included in a
multivariate analysis using a forward stepwise
binary logistic regression model, where nega-
tive PET-2 scan was considered a dependent
variable. Only P-values ≤0.05 were considered
to be statistically significant.
Results Characteristics of patients 
The demographic and clinical characteris-
tics of 20 cHL patients (6 males and 14
females, mean follow up 35 months, range 8-
60) are shown in Table 1. The mean age at
diagnosis was 33 years (range 18-61). The
large majority of patients (70%) had a nodular
sclerosing histological subtype. All patients
belonged to advanced Ann Arbor stages (IIb-
IV).Characteristics of controls
Eight deceased subjects (4 females and 4
males) underwent standard immunologic
characterization procedures for organ dona-
tion, were used as controls. The median age
was 32 years, ranging from 17 to 75. The lym-
phonodes obtained from each subject varied in
number, from one to three, and in size, from 1
mm to 15 mm.
Progression-free survival followingtreatment and according to PET-2outcome
In the cohort of 20 patients, 4-year PFS was
70.5%. PFS was significantly higher in patients
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Table 1. Characteristics of 20 patients with advanced-stage classical Hodgkin lymphoma. 
                                                                                           Patients (n=20)
Sex  (n, %)                                                                                                                              
        Male                                                                                                                      6    (30.0)
        Female                                                                                                                14   (70.0)
Age at diagnosis (mean, range)                                                                            33 (18-61)
Disease  subtype  (n, %)                                                                                                     
        Nodular sclerosing                                                                                           14   (70.0)
        Mixed-cellularity                                                                                                4    (12.5)
        Lymphocyte-rich                                                                                                2    (10.0)
        Lymphocyte-depleted                                                                                       0    (0.0)
        Albumin, g/dL, (mean, range)                                                                       3.9 (2.51-4.68)
        Hemoglobin, g/dL, (mean, range)                                                               12.9 (8.7-14.8)
        Lymphocytes, x103/uL, (mean, range)                                                        1.70 (0.5-3.3)
        Neutrophils, x103/uL, (mean, range)                                                           8.6 (2.7-18.8)
        Bulky mass (n, %)                                                                                             12   (60.0)
        B symptoms (n, %)                                                                                           19   (95.0)
        Extranodal extension (n, %)                                                                           9    (45.0)
        IPS score ≥4                                                                                                       2    (10.0) 
Ann Arbor stage 2b (n, %)                                                                                      9    (45.0)
        Stage 3  (n, %)                                                                                                   7    (35.0)
        Stage 4  (n, %)                                                                                                   4    (12.5)
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with negative PET-2 compared to positive PET-
2 (85.6% vs 40%, P=0.003) Of the five intensi-
fied patients: 4 underwent to autologous and 1
allogeneic HST. In univariate analysis, an HLA-
G HRS cell staining score of >1 was independ-
ently associated with the probability of achiev-
ing a negative PET-2 result (P<0.01). 
HLA-G expression in lymphonodesections from cHL patients andcontrols
Table 2 shows the expression of HLA-G in
lymphonodes from 20 cHL patients and 8 con-
trols. The median score of HLA-G expression in
lymphocytes was 2 (26-50% of lymphocytes
showed HLA-G+) in cHL patients compared to
1 (1-25% of lymphocytes showed HLA-G+) in
controls. An HLA-G score of ≥2 was present in
13/20 patients in comparison to 1/8 donors
(65% vs 12,5%, p= 0.033) (Figure 1).  The
median score of HLA-G expression in histio-
cytes was 1 (1-25% of histiocytes showed HLA-
G+) both in patients and controls; an HLA-G
score of ≥2 was found in 9/20 patients com-
pared to 3/8 donors (45% vs 37.5%, P=NS).
11/20 patients (55%) showed HLA-G+ HRS
cells. The median score for HRS cells HLA-G
expression was 1 (1-25% of HRS cells were
HLA-G+). Relationship between HLA-Gexpression in lymphonode sectionsfrom cHL patients and PET-2results
We found that 80% of patients with PET-2
positivity had an HLA-G staining score for lym-
phocytes of ≥2 compared to 60% of PET-2 neg-
ative patients; this difference did not reach
statistical significance (P=0.08); conversely,
none of the PET-2 positive patients showed
HLA-G+ HRS cells with a staining score of ≥2,
in comparison to 40% of PET-2 negative
patients (P=0.09, not significant). Figure 2
shows HLA-G expression in 2 patients with dif-
ferent PET-2 outcomes. HLA-G expression in lymphonodesections from cHL patients accord-ing to the HLA-G 14-bp polymor-phism
Patients homozygotes for the 14-bp deletion
polymorphism (del/del) showed a trend,
although not statistically significant, for high-
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Table 2. HLA-G staining in patients with advanced-stage classical Hodgkin lymphoma and controls. According to HLA-G diffusion,
the following scores were assigned: 0 for negative staining (-), 1 for staining <25% (-+), 2 between 26 and 50% (+), 3 between 51 and
75% (++), 4 between 76 and 100% (+++).
Patients  Disease  subtype             Lymphocytes        Lymphocytes               Histiocytes       Histiocytes                    HRS cell       HRS cell
                                                             HLA-G +               HLA-G +                     HLA-G +            HLA-G +                      HLA-G +       HLA-G +
                                                                   %                        Score                             %                    Score                              %               Score
1                                   LR                                          +++                                 4                                          ++                             3                                         +++                      4
2                                   NS                                              -                                     0                                            -                                0                                             -                          0
3                                   NS                                              -                                     0                                            -                                0                                             +                         2
4                                   NS                                             +                                    2                                          ++                             3                                            -+                        1
5                                   NS                                              -                                     0                                          -+                              1                                            -+                        1
6                                   NS                                             +                                    2                                          -+                              1                                             -                          0
7                                   NS                                             -+                                   1                                          -+                              1                                            -+                        1
8                                   NS                                             -+                                   1                                          -+                              1                                             +                         2
9                                   NS                                            ++                                  3                                          -+                              1                                             +                         2
10                                 NS                                          +++                                 4                                           +                               2                                            -+                        1
11                                 NS                                             -+                                   1                                          -+                              1                                             -                          0
12                                 NS                                             +                                    2                                          -+                              1                                             -                          0
13                                 NS                                             +                                    2                                           +                               2                                             -                          0
14                                MC                                             +                                    2                                        +++                            4                                             -                          0
15                                 NS                                             +                                    2                                           +                               2                                             -                          0
16                                MC                                          +++                                 4                                            -                                0                                            -+                        1
17                                 LR                                            ++                                  3                                          -+                              1                                            -+                        1
18                                 NS                                             -+                                   1                                           +                               2                                             +                         2
19                                MC                                           ++                                  3                                           +                               2                                             -                          0
20                                 NS                                          +++                                 4                                           +                               2                                             -                          0
Median                                                                                                              2                                                                            1                                                                       1
Controls                                                                                                                                                                                                       
1                                                                                    -+                                   1                                          -+                              1                                                                        
2                                                                                    -+                                   1                                          -+                              1                                                                          
3                                                                                    -+                                   1                                            -                                0                                                                        
4                                                                                     -                                     0                                            -                                0                                                                          
5                                                                                    -+                                   1                                           +                               2                                                                        
6                                                                                    +                                    2                                           +                               2                                                                          
7                                                                                    -+                                   1                                           +                               2                                                                        
8                                                                                    -+                                   1                                          -+                              1                                                                          
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er HLA-G expression with a staining score of
≥2, compared to in/in patients (100% vs 50% of
cases in lymphocytes; 75% vs 0% in histiocytes;
50% vs 25% in HRS cells). Fisher exact test
showed a significant association between
homozygosity in/in and lower expression of
HLA-G on HRS cells (P=0.01). Figure 3 shows
HLA-G expression in 2 patients homozygous
for the insertion (in/in) and deletion (del/del)
polymorphism, respectively. 
Discussion
Our study, albeit limited by the relatively
small number of patients, allows us to make
some considerations. Firstly, HLA-G protein
expression was higher in lymphonodes from
cHL patients than controls.  Moreover, HRS
cells were immunoreactive for HLA-G in 55% of
the patients, which is in agreement with previ-
ously published data.14 Conversely, our find-
ings do not confirm the very low percentage of
HLA-G staining previously observed for histio-
cytes and lymphocytes in the tumor microenvi-
ronment.14 Indeed, we found significantly
higher staining scores (≥2) for HLA-G protein
expression in lymphocytes of patients com-
pared to the controls (65% vs 12,5%, P=0.033)
(Table 2, Figure 1).  This finding is coherent
with the hypothesis that HLA-G molecule
determines a tolerogenic status through down-
regulation of immune response by cells of the
tumor microenvironment, leading to survival
of the neoplastic cell. 
A second important finding emerging from
our study was that different patterns of HLA-G
protein expression in both the tumor microen-
vironment and HRS cells were associated with
different clinical outcomes. In line with other
studies,15 Patients with negative PET-2 had
significantly higher PFS rates than patients
with a positive PET-2 scan (85.6% vs 40%,
P=0.003). In the group of PET-2 positive
patients, we observed a higher HLA-G protein
expression on lymphocytes and a lower expres-
sion on HRS cells (Figure 2). Conversely, PET-
2 negative patients had higher HLA-G protein
expression levels on HRS cells compared to the
tumor microenvironment (Figure 2). Classical
HL represents an interesting study model for
the assessment of immunologic and immuno-
genetic factors that may confer susceptibility
to tumors or facilitate tumor immune escape
mechanisms.4,19-22 HLA-G molecules might
have a key role in impaired NK cell function
through interaction with ILT2 and KIR2DL4
receptors expressed on NK cell surface that
inhibit their cytotoxicity, IFN-  secretion and
chemotaxis.20,23,24 However, since HRS cells
pertain to the B-cell lineage, it is also possible
that they express HLA-G inhibitory receptors,
that would imply a direct anti-proliferative
effect on the tumor.  In-vitro data have shown
that negative signaling mediated by HLA-G
down-regulates proliferation of the tumor in
human B-cell lymphomas, myelomas and B-cell
leukemia.11 The different immunohistochemi-
cal expression of HLA-G protein observed in
our study for HRS cells compared to the sur-
rounding microenvironment may suggest a
model similar to that hypothesized by
Carosella et al.5 (Figure 4a). Higher HLA-G
expression in the tumor microenvironment
surrounding HRS cells could favor an immune-
escape mechanism (Figure 4b), whereas high-
er HLA-G expression in HRS cells could offer
better control of tumor proliferative activity
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Figure 1. Immunohistochemical staining of HLA-G expression (brown color) in a control
(left) and in an advanced-stage cHL patient (right) with a larger number of immunopos-
itive reactive cells and a Reed-Sternberg cell (RS) (magnification: 40 HPF).
Figure 2. HLA-G expression (brown color) according to PET-2 results. Left: a 45 year-old
female with negative PET-2. The patient shows low HLA-G protein expression in lym-
phocytes; conversely, Reed-Srernberg cells (RS) are stained. Right: HLA-G is more
expressed in reactive cells then in Reed-Srernberg cells (RS) in a 37 year-old female with
positive PET 2 (magnification: 40 HPF).
Figure 3. HLA-G expression (brown color) according to the HLA-G 14-bp polymorphism
in cHL. Left: a 32 year-old female, homozygous for the 14-bp insertion (in/in). Right: a
46 year-old male, homozygous for the14-bp deletion (del/del). HLA-G expression is high-
er in the del/del patient sample. RS, Reed-Sternberg cells (magnification: 40 HPF).
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(Figure 4c).  Hence, HLA-G could exert a dual
role: i) tumor escape mediated by HLA-G-dri-
ven inhibitory mechanisms of antitumor
response; and ii) tumor antiproliferative func-
tion. According with this hypothesis, the final
effect on tumor progression might derive from
the balance between these two mechanisms.23
Regarding the potential influence of the HLA-G
14-bp polymorphism on tissue expression,
although not statistically significant, patients
homozygous for the del/del polymorphism
showed a trend to a higher expression of HLA-
G protein both in the microenvironment and
neoplastic cells as compared to patients with
the in/in genotype (Figure 3). The del/del
genotype was associated with more stable
mRNA and higher HLA-G expression, reduced
overall survival in CLL and diffuse large B-cell
lymphomas (DLBCL).12,13,25,26 Our data revealed
a significant association between the HLA-G
in/in genotype and lower expression of HLA-G
on HRS cells. 
Finally, the present study is the first to pro-
vide evidence of different patterns of HLA-G
protein expression in HRS cells and the sur-
rounding tumor microenvironment of lym-
phonodes from cHL patients. In our opinion,
our data suggest that the immunoreactive pat-
tern for HLA-G in the lymphnodes of patients
affected by cHL might represent a useful tool
for therapeutic purposes. Eventhough survival
of advanced-stage cHL patients has increased
to 70-85%, the optimal balance of the risks and
benefits of treatment is still a matter of debate.
The main dilemma remains whether frontline
intensive chemotherapy should be given to all
patients or be restricted to patients who are
poor responders to standard treatment
approaches. For this reason, new predictive
factors for prognosis and response to treat-
ment in cHL are important goals. Within this
contest, HLA-G expression may represent a
potential biomarker able to predict a response
to treatment and our results may enforce the
rationale for developing innovative and target-
ed treatments in cHL patients, based on the
modulation of HLA-G function.
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